INVVY - Indivior posts data from buprenorphine-fentanyl trial to treat respiratory depression

Indivior (OTCPK:INVVY) announced modeling data testing the interaction between buprenorphine, a treatment for opioid use disorder (OUD), and fentanyl, a synthetic opioid, to check how buprenorphine can reduce fentanyl-induced respiratory depression. The company said the modeling data indicated that buprenorphine plasma concentrations of 2 mL and higher could protect against fentanyl-induced respiratory depression in chronic opioid users, with a reduced probability of apnea. The data showed that when mu-opioid receptor (MOR) occupancy by buprenorphine is sufficiently high, fentanyl is unable to activate the MOR and consequently will not cause additional respiratory depression, the company said. INVVY published the data online on JCI Insight.

For further details see:

Indivior posts data from buprenorphine-fentanyl trial to treat respiratory depression